Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW4421S-T3
- Development stage
- Unknown
- Lead developer
- Daewon Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**DW4421S-T3** is a 30 mg oral tablet formulation of padoprazan, a small-molecule potassium-competitive acid blocker developed for gastroesophageal reflux disease. It competitively inhibits the potassium-binding site of the gastric hydrogen-potassium ATPase, producing rapid and potent suppression of gastric acid secretion. The formulation was evaluated as a once-daily, 7-day regimen in cohort 5 of a Phase 1 multiple-ascending-dose study in healthy adults. The broader padoprazan program is being advanced by Daewon Pharmaceutical in South Korea for erosive and non-erosive gastroesophageal reflux disease.
02
Targets
αVβ3 (Integrin αVβ3)TRα1-p43 (Thyroid hormone receptor alpha 1, mitochondrial (p43))THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on DW4421S-T3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DW4421S-T3.